GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » E10

uniQure NV (uniQure NV) E10 : $-2.78 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

uniQure NV's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.360. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2.78 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-03), uniQure NV's current stock price is $5.32. uniQure NV's E10 for the quarter that ended in Mar. 2024 was $-2.78. uniQure NV's Shiller PE Ratio of today is .


uniQure NV E10 Historical Data

The historical data trend for uniQure NV's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV E10 Chart

uniQure NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -2.28 -2.69

uniQure NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.39 -2.48 -2.63 -2.69 -2.78

Competitive Comparison of uniQure NV's E10

For the Biotechnology subindustry, uniQure NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where uniQure NV's Shiller PE Ratio falls into.



uniQure NV E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, uniQure NV's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.36/128.5800*128.5800
=-1.360

Current CPI (Mar. 2024) = 128.5800.

uniQure NV Quarterly Data

per share eps CPI Adj_EPS
201406 -0.696 99.240 -0.902
201409 -0.647 99.960 -0.832
201412 -0.956 99.050 -1.241
201503 -0.747 99.750 -0.963
201506 -0.976 100.230 -1.252
201509 -1.215 100.500 -1.554
201512 -0.693 99.730 -0.893
201603 -0.900 100.310 -1.154
201606 -0.840 100.260 -1.077
201609 -0.610 100.570 -0.780
201612 -0.580 100.710 -0.741
201703 -0.800 101.440 -1.014
201706 -0.830 101.370 -1.053
201709 -0.400 102.030 -0.504
201712 -0.910 101.970 -1.147
201803 -0.590 102.470 -0.740
201806 -0.570 103.100 -0.711
201809 -0.590 103.950 -0.730
201812 -0.590 103.970 -0.730
201903 -0.740 105.370 -0.903
201906 -0.830 105.840 -1.008
201909 -0.580 106.700 -0.699
201912 -0.970 106.800 -1.168
202003 -0.630 106.850 -0.758
202006 -0.960 107.510 -1.148
202009 -1.210 107.880 -1.442
202012 -0.010 107.850 -0.012
202103 -0.910 108.870 -1.075
202106 8.510 109.670 9.977
202109 -0.790 110.790 -0.917
202112 0.170 114.010 0.192
202203 -1.000 119.460 -1.076
202206 -0.840 119.050 -0.907
202209 -1.020 126.890 -1.034
202212 0.150 124.940 0.154
202303 -1.630 124.720 -1.680
202306 -1.440 125.830 -1.471
202309 -1.880 127.160 -1.901
202312 -1.530 126.450 -1.556
202403 -1.360 128.580 -1.360

Add all the adjusted EPS together and divide 10 will get our e10.


uniQure NV  (NAS:QURE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


uniQure NV E10 Related Terms

Thank you for viewing the detailed overview of uniQure NV's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


uniQure NV (uniQure NV) Business Description

Traded in Other Exchanges
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Executives
Walid Abi-saab officer: Chief Medical Officer C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Ricardo Dolmetsch officer: President, R&D 113 HARTWELL AVENUE, LEXINGTON MA 02421
Pierre Caloz officer: Chief Operating Officer UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Madhavan Balachandran director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Gut director C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post director
Christian Klemt officer: Chief Financial Officer PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Jeremy P. Springhorn director C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Matthew C Kapusta director, officer: CEO, Managing Director 7358 MCVAY ROAD, GERMANTOWN TN 38138
Kuta Alexander Edward Iii officer: Executive VP, Operations 239 WILLIS ROAD, SUDBURY MA 01776